Authors:
Bibawi, S
Abi-Said, D
Fayad, L
Anderlini, P
Ueno, NT
Mehra, R
Khouri, I
Giralt, S
Gajewski, J
Donato, M
Claxton, D
Braunschweig, I
van Besien, K
Andreeff, M
Andersson, BS
Estey, EH
Champlin, R
Przepiorka, D
Citation: S. Bibawi et al., Thiotepa, busulfan, and cyclophosphamide as a preparative regimen for allogeneic transplantation for advanced myelodysplastic syndrome and acute myelogenous leukemia, AM J HEMAT, 67(4), 2001, pp. 227-233
Authors:
Beran, M
Shen, Y
Kantarjian, H
O'Brien, S
Koller, CA
Giles, FJ
Cortes, J
Thomas, DA
Faderl, S
Despa, S
Estey, EH
Citation: M. Beran et al., High-dose chemotherapy in high-risk myelodysplastic syndrome - Covariate-adjusted comparison of five regimens, CANCER, 92(8), 2001, pp. 1999-2015
Authors:
Giles, FJ
Kantarjian, HM
Kornblau, SM
Thomas, DA
Garcia-Manero, G
Waddelow, TA
David, CL
Phan, AT
Colburn, DE
Rashid, A
Estey, EH
Citation: Fj. Giles et al., Mylotarg(TM) (gemtuzumab ozogamicin) therapy is associated with hepatic venoocclusive disease in patients who have not received stem cell transplantation, CANCER, 92(2), 2001, pp. 406-413
Authors:
Estey, EH
Thall, PF
Cortes, JE
Giles, FJ
O'Brien, S
Pierce, SA
Wang, XM
Kantarjian, HM
Beran, M
Citation: Eh. Estey et al., Comparison of idarubicin plus ara-C-, fludarabine plus ara-C-, and topotecan plus ara-C-based regimens in treatment of newly diagnosed acute myeloid leukemia, refractory anemia with excess blasts in transformation, or refractory anemia with excess blasts, BLOOD, 98(13), 2001, pp. 3575-3583
Citation: Pf. Thall et Eh. Estey, Graphical methods for evaluating covariate effects in the Cox model, HANDBOOK OF STATISTICS IN CLINICAL ONCOLOGY, 2001, pp. 411-432
Authors:
Ibrahim, S
Estey, EH
Pierce, S
Glassman, A
Keating, M
O'Brien, S
Kantarjian, HM
Albitar, M
Citation: S. Ibrahim et al., 11q23 Abnormalities in patients with acute myelogenous leukemia and myelodysplastic syndrome as detected by molecular and cytogenetic analyses, AM J CLIN P, 114(5), 2000, pp. 793-797
Citation: Eh. Estey et al., Identification of a group of AML/MDS patients with a relatively favorable prognosis who have chromosome 5 and/or 7 abnormalities, HAEMATOLOG, 85(3), 2000, pp. 246-249
Citation: Eh. Estey et al., Effect of time to complete remission on subsequent survival and disease-free survival time in AML, RAEB-t, and RAEB, BLOOD, 95(1), 2000, pp. 72-77
Authors:
Weinkauff, R
Estey, EH
Starostik, P
Hayes, K
Huh, YO
Hirsch-Ginsberg, C
Andreeff, M
Keating, M
Kantarjian, HM
Freireich, EJ
Albitar, M
Citation: R. Weinkauff et al., Use of peripheral blood blasts vs bone marrow blasts for diagnosis of acute leukemia, AM J CLIN P, 111(6), 1999, pp. 733-740
Authors:
Aboul-Nasr, R
Estey, EH
Kantarjian, HM
Freireich, EJ
Andreeff, M
Johnson, BJ
Albitar, M
Citation: R. Aboul-nasr et al., Comparison of touch imprints with aspirate smears for evaluating bone marrow specimens, AM J CLIN P, 111(6), 1999, pp. 753-758
Authors:
Estey, EH
Thall, PF
Reed, P
Kantarjian, H
Beran, M
Pierce, S
Keating, MJ
Citation: Eh. Estey et al., Treatment of newly diagnosed AML, RAEB-t or RAEB with lisofylline or placebo in addition to chemotherapy, LEUKEMIA, 13(6), 1999, pp. 850-854
Citation: Jf. Seymour et al., Secondary acute myeloid leukemia with inv(16): report of two cases following paclitaxel-containing chemotherapy and review of the role of intensifiedara-C therapy, LEUKEMIA, 13(11), 1999, pp. 1735-1740
Authors:
Andreeff, M
Jiang, S
Zhang, X
Konopleva, M
Estrov, Z
Snell, VE
Xie, Z
Okcu, MF
Sanchez-Williams, G
Dong, J
Estey, EH
Champlin, RC
Kornblau, SM
Reed, JC
Zhao, S
Citation: M. Andreeff et al., Expression of Bcl-2-related genes in normal and AML progenitors: changes induced by chemotherapy and retinoic acid, LEUKEMIA, 13(11), 1999, pp. 1881-1892
Citation: Pf. Thall et al., A new statistical method for dose-finding based on efficacy and toxicity in early phase clinical trials, INV NEW DR, 17(2), 1999, pp. 155-167
Authors:
Cortes, JE
Kantarjian, HM
O'Brien, S
Giles, F
Keating, MJ
Freireich, EJ
Estey, EH
Citation: Je. Cortes et al., A pilot study of interleukin-2 for adult patients with acute myelogenous leukemia in first complete remission, CANCER, 85(7), 1999, pp. 1506-1513
Authors:
Estrov, Z
Manna, SK
Harris, D
Van, Q
Estey, EH
Kantarjian, HM
Talpaz, M
Aggarwal, BB
Citation: Z. Estrov et al., Phenylarsine oxide blocks interleukin-1 beta-induced activation of the nuclear transcription factor NF-kappa B, inhibits proliferation, and induces apoptosis of acute myelogenous leukemia cells, BLOOD, 94(8), 1999, pp. 2844-2853
Authors:
Estey, EH
Thall, PF
Pierce, S
Cortes, J
Beran, M
Kantarjian, H
Keating, MJ
Andreeff, M
Freireich, E
Citation: Eh. Estey et al., Randomized phase II study of fludarabine plus cytosine arabinoside plus idarubicin +/- all-trans retinoic acid +/- granulocyte colony-stimulating factor in poor prognosis newly diagnosed acute myeloid leukemia and myelodysplastic syndrome, BLOOD, 93(8), 1999, pp. 2478-2484
Authors:
Konopleva, M
Mikhail, A
Estrov, Z
Zhao, SR
Harris, D
Sanchez-Williams, G
Kornblau, SM
Dong, J
Kliche, KO
Jiang, SW
Snodgrass, HR
Estey, EH
Andreeff, M
Citation: M. Konopleva et al., Expression and function of leptin receptor isoforms in myeloid leukemia and myelodysplastic syndromes: Proliferative and anti-apoptotic activities, BLOOD, 93(5), 1999, pp. 1668-1676